Tuesday, 28 July 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 28 July 2026
News

Aussie blight on booming drug

Posted 28 July 2026 AM

Johnson & Johnson has a drug that's taking off globally and replacing the revenue lost from its blockbuster Stelara going off patent but it's not seeing the same joy in Australia.

"Tremfya remains the fastest-growing advanced therapy in both Crohn's disease and ulcerative colitis, delivering exceptional overall sales growth of 71 per cent in the [second] quarter," J&J CEO, Joaquin Duato, told an earnings call.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (20)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.